U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07418177) titled 'Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMD' on Jan. 09.
Brief Summary: Phase I Study of the Safety and Preliminary Efficacy of Human induced pluripotent stem cells-derived Retinal Pigment Epithelial (HiPSC-RPE) Cells Subretinal Transplantation in Late-Stage Age-Related Macular Degeneration(AMD) Patients
Study Start Date: Feb. 10
Study Type: INTERVENTIONAL
Condition:
AMD - Age-Related Macular Degeneration
Intervention:
BIOLOGICAL: HiPSC-RPE cells
HiPSC-RPE cells transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure
DRUG: Erlotinib (150 ...